Zobrazeno 1 - 10
of 567
pro vyhledávání: '"R. Dudczak"'
Publikováno v:
Oncology. 83:45-49
Objective: Vascular endothelial growth factor (VEGF) is an important angiogenic factor, and its receptors have been shown to be overexpressed in various human carcinomas. In this study, we investigated the role of scanning with iodine-123 (123I)-labe
Autor:
C. Novotny, A. Kurtaran, M. Leimer, M. Raderer, B. Fuger, Thomas Pangerl, Irene Virgolini, F. Andreae, P. Angelberger, P. Patri, S. R. Li, R. Dudczak, G. Burggasser, T. Traub
Publikováno v:
Current Pharmaceutical Design. 8:1781-1807
The high level expression of somatostatin receptors (SSTR) on various tumor cells has provided the molecular basis for successful use of radiolabeled octreotide / lanreotide analogs as tumor tracers in nuclear medicine. Other (nontumoral) potential i
Publikováno v:
LaboratoriumsMedizin. 26:191-202
Summary: Efficacy data as well as correlations of test results measured by different automated immunoassay analysers are obligatory for organisational and medical decisions on a rational scientific basis. Thus, we compared the serum concentrations of
Publikováno v:
Diabetes. 44:543-549
Autor:
A, Khorsand, M, Gyöngyösi, H, Sochor, G, Maurer, G, Karanikas, R, Dudczak, E, Schuster, G, Porenta, S, Graf
Publikováno v:
Nuklearmedizin. Nuclear medicine. 50(1)
We compared and delineated possible differences of model-based analysis of ECG-gated SPECT using (⁹⁹m)Tc-sestamibi (Tc-SPECT) with ECG-gated ¹⁸F-fluorodeoxyglucose-PET (FDG-PET) for determination of end-diastolic (EDV) and end-systolic (ESV) c
Autor:
C. Dittrich, M. Baur, R. Mader, O. Schlappack, R. Dudczak, T. Leitha, R. Lenzhofer, S. Hoffmann, L. Vieder, U. Heberle, M. Kaul, B. Greifenberg
Publikováno v:
Europe PubMed Central
A phase I-II study of weekly low-dose pirarubicin was performed in 19 patients with advanced breast cancer. The goal was to establish the optimal dose intensity, i.e., the maximal dose applicable at tolerable toxicity within the intended schedule. Ea
Publikováno v:
Radiotherapy and Oncology. 102:S109-S110